

## DAFTAR PUSTAKA

- Armstrong, A. W., & Read, C. (2020). Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. *JAMA - Journal of the American Medical Association*, 323(19), 1945–1960.  
<https://doi.org/10.1001/jama.2020.4006>
- Banerjee, A., & Chaudhury, S. (2010). Statistics without tears: Populations and samples. *Industrial Psychiatry Journal*, 19(1), 60.  
<https://doi.org/10.4103/0972-6748.77642>
- Blauvelt, A., Papp, K., Gottlieb, A., Jarell, A., Reich, K., Maari, C., Gordon, K. B., Ferris, L. K., Langley, R. G., Tada, Y., Lima, R. G., Elmaraghy, H., Gallo, G., Renda, L., Park, S. Y., Burge, R., Bagel, J., Vender, R., Lomaga, M. A., ... Fried, R. (2020a). A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. In *British Journal of Dermatology* (Vol. 182, Issue 6, pp. 1348–1358).  
<https://doi.org/10.1111/bjd.18851>
- Blauvelt, A., Papp, K., Gottlieb, A., Jarell, A., Reich, K., Maari, C., Gordon, K. B., Ferris, L. K., Langley, R. G., Tada, Y., Lima, R. G., Elmaraghy, H., Gallo, G., Renda, L., Park, S. Y., Burge, R., Bagel, J., Vender, R., Lomaga, M. A., ... Fried, R. (2020b). A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. *British Journal of Dermatology*, 182(6), 1348–1358.  
<https://doi.org/10.1111/bjd.18851>
- Blauvelt, Andrew, Papp, K. A., Griffiths, C. E. M., Randazzo, B., Wasfi, Y., Shen, Y. K., Li, S., & Kimball, A. B. (2017). Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe

psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-. *Journal of the American Academy of Dermatology*, 76(3), 405–417. <https://doi.org/10.1016/j.jaad.2016.11.041>

Brownstone, N. D., Hong, J., Mosca, M., Haderler, E., Liao, W., Bhutani, T., & Koo, J. (2021). Biologic treatments of psoriasis: An update for the clinician. *Biologics: Targets and Therapy*, 15, 39–51. <https://doi.org/10.2147/BTT.S252578>

Coates, L. C., & Helliwell, P. S. (2017). Psoriatic arthritis: state of the art review. *Clinical Medicine*, 17(1), 65. <https://doi.org/10.7861/CLINMEDICINE.17-1-65>

Di Meglio, P., Villanova, F., & Nestle, F. O. (2014). Psoriasis. *Cold Spring Harbor Perspectives in Medicine*, 4(8). <https://doi.org/10.1101/cshperspect.a015354>

Eli Lilly Canada Inc. (2018). *Clinical Review Report: Ixekizumab*.

Evgenia, T., ZZ, Y., C, B., L, C., M, G., LA, J., L, M., RB, W., & CE, G. (2016). Early- and late-onset psoriasis: a cross-sectional clinical and immunocytochemical investigation. *The British Journal of Dermatology*, 175(5), 1038–1044. <https://doi.org/10.1111/BJD.14886>

Gelfand, J. M., Shin, D. B., Alavi, A., Torigian, D. A., Werner, T., Papadopoulos, M., Takeshita, J., Noe, M. H., Dey, A. K., Playford, M. P., & Mehta, N. N. (2020). A Phase IV, Randomized, Double-Blind, Placebo-Controlled Crossover Study of the Effects of Ustekinumab on Vascular Inflammation in Psoriasis (the VIP-U Trial). *Journal of Investigative Dermatology*, 140(1), 85-93.e2. <https://doi.org/10.1016/j.jid.2019.07.679>

Gordon, K. B., Armstrong, A. W., Foley, P., Song, M., Shen, Y. K., Li, S., Muñoz-Elías, E. J., Branigan, P., Liu, X., & Reich, K. (2019). Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study. *Journal of Investigative Dermatology*, 139(12), 2437-2446.e1.

<https://doi.org/10.1016/j.jid.2019.05.016>

- Gottlieb, A. B., Blauvelt, A., Thaçi, D., Leonardi, C. L., Poulin, Y., Drew, J., Peterson, L., Arendt, C., Burge, D., & Reich, K. (2018). Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2). *Journal of the American Academy of Dermatology*, 79(2), 302-314.e6. <https://doi.org/10.1016/j.jaad.2018.04.012>
- Harahap, M. (2015). *Ilmu Penyakit Kulit*. Hipokrates.
- Hawkes, J. E., Chan, T. C., & Krueger, J. G. (2017). Psoriasis pathogenesis and the development of novel targeted immune therapies. *Journal of Allergy and Clinical Immunology*, 140(3), 645–653. <https://doi.org/10.1016/J.JACI.2017.07.004>
- Kamata, M., & Tada, Y. (2020). Efficacy and Safety of Biologics for Psoriasis and Psoriatic Arthritis and Their Impact on Comorbidities: A Literature Review. *International Journal of Molecular Sciences*, 21(5). <https://doi.org/10.3390/IJMS21051690>
- Kamiya, K., Kishimoto, M., Sugai, J., Komine, M., & Ohtsuki, M. (2019). Risk Factors for the Development of Psoriasis. *International Journal of Molecular Sciences*, 20(18). <https://doi.org/10.3390/IJMS20184347>
- Kang, S., Amagai, M., Bruckner, A. L., Enk, A. H., Margolis, D. J., McMichael, A. J., & Orringer, J. S. (2019). *Fitzpatrick's Dermatology in General Medicine, 9th Edition* (9th ed.). McGraw-Hill.
- Krueger, J. G., Wharton, K. A., Schlitt, T., Suprun, M., Torene, R. I., Jiang, X., Wang, C. Q., Fuentes-Duculan, J., Hartmann, N., Peters, T., Koroleva, I., Hillenbrand, R., Letzkus, M., Yu, X., Li, Y., Glueck, A., Hasselberg, A., Flannery, B., Suárez-Fariñas, M., & Hueber, W. (2019). IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis. *Journal of Allergy and Clinical Immunology*, 144(3), 750–763. <https://doi.org/10.1016/j.jaci.2019.04.029>

- Lebwohl, M., Blauvelt, A., Paul, C., Sofen, H., Węglowska, J., Piguët, V., Burge, D., Rolleri, R., Drew, J., Peterson, L., & Augustin, M. (2018). Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT). *Journal of the American Academy of Dermatology*, *79*(2), 266-276.e5. <https://doi.org/10.1016/j.jaad.2018.04.013>
- Mayasari, R. (2019). *AgenBiologik Psoriasis Terkini*. *57*, 62–75.
- Mease, P. J., Genovese, M. C., Weinblatt, M. E., Peloso, P. M., Chen, K., Othman, A. A., Li, Y., Mansikka, H. T., Khatri, A., Wishart, N., & Liu, J. (2018). Phase II Study of ABT-122, a Tumor Necrosis Factor– and Interleukin-17A–Targeted Dual Variable Domain Immunoglobulin, in Patients With Psoriatic Arthritis With an Inadequate Response to Methotrexate. *Arthritis and Rheumatology*, *70*(11), 1778–1789. <https://doi.org/10.1002/art.40579>
- Mease, P. J., Gladman, D. D., Deodhar, A., McGonagle, D. G., Nash, P., Boehncke, W. H., Gottlieb, A., Xu, X. L., Xu, S., Hsia, E. C., Karyekar, C. S., & Helliwell, P. S. (2020). Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study. *RMD Open*, *6*(2), 1–10. <https://doi.org/10.1136/rmdopen-2020-001217>
- Mease, P. J., Helliwell, P. S., Hjulter, K. F., Raymond, K., & McInnes, I. (2021). Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials. *Annals of the Rheumatic Diseases*, *80*(2), 185–193. <https://doi.org/10.1136/annrheumdis-2019-216835>
- Menaldi, S. linusih sw, Bramono, K., & Indriatmi, W. (2016). *Ilmu penyakit kulit dan kelamin* (Edisi ke-7). Fakultas Kedokteran Universitas Indonesia.
- Nair, P. A., & Badri, T. (2020). Psoriasis. In *StatPearls*. StatPearls Publishing. <http://www.ncbi.nlm.nih.gov/pubmed/28846344>

- Ohtsuki, M., Fujita, H., Watanabe, M., Suzaki, K., Flack, M., Huang, X., Kitamura, S., Valdes, J., & Igarashi, A. (2019). Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the SustaIMM phase 2/3 trial. *Journal of Dermatology*, *46*(8), 686–694. <https://doi.org/10.1111/1346-8138.14941>
- Ohtsuki, M., Kubo, H., Morishima, H., Goto, R., Zheng, R., & Nakagawa, H. (2018). Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study. *Journal of Dermatology*, *45*(9), 1053–1062. <https://doi.org/10.1111/1346-8138.14504>
- Papp, K. A., Blauvelt, A., Bukhalo, M., Gooderham, M., Krueger, J. G., Lacour, J.-P., Menter, A., Philipp, S., Sofen, H., Tying, S., Berner, B. R., Visvanathan, S., Pamulapati, C., Bennett, N., Flack, M., Scholl, P., & Padula, S. J. (2017). Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis. *New England Journal of Medicine*, *376*(16), 1551–1560. <https://doi.org/10.1056/nejmoa1607017>
- Papp, K. A., Merola, J. F., Gottlieb, A. B., Griffiths, C. E. M., Cross, N., Peterson, L., Cioffi, C., & Blauvelt, A. (2018). Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial. *Journal of the American Academy of Dermatology*, *79*(2), 277-286.e10. <https://doi.org/10.1016/j.jaad.2018.03.037>
- Parisi, R., Iskandar, I. Y. K., Kontopantelis, E., Augustin, M., Griffiths, C. E. M., & Ashcroft, D. M. (2020). National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. *The BMJ*, *369*. <https://doi.org/10.1136/BMJ.M1590>
- Pasina, L., Casadei, G., & Nobili, A. (2016). Biological agents and biosimilars: Essential information for the internist. *European Journal of Internal*

*Medicine*, 33, 28–35. <https://doi.org/10.1016/J.EJIM.2016.06.005>

Reich, K., Griffiths, C. E. M., Gordon, K. B., Papp, K. A., Song, M., Randazzo, B., Li, S., Shen, Y. K., Han, C., Kimball, A. B., Armstrong, A. W., Foley, P., & Blauvelt, A. (2020). Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials. *Journal of the American Academy of Dermatology*, 82(4), 936–945. <https://doi.org/10.1016/j.jaad.2019.11.040>

Rendon, A., & Schäkel, K. (2019). Psoriasis Pathogenesis and Treatment. *International Journal of Molecular Sciences*, 20(6). <https://doi.org/10.3390/IJMS20061475>

Van Cranenburgh, O. D., De Korte, J., Sprangers, M. A. G., De Rie, M. A., & Smets, E. M. A. (2013). Satisfaction with treatment among patients with psoriasis: A web-based survey study. *British Journal of Dermatology*, 169(2), 398–405. <https://doi.org/10.1111/BJD.12372>

Virendra N, S., Prashant, V., & Ananta, K. (2014). Anthralin/dithranol in dermatology. *International Journal of Dermatology*, 53(10), e449–e460. <https://doi.org/10.1111/J.1365-4632.2012.05611.X>